Abstract
Summary
Global genetic testing market is expected to reach USD 62,607,580.19 thousand by 2031 from USD 18,810,536.39 thousand in 2023, growing at a CAGR of 16.5% during the forecast period of 2024 to 2031.
Market Segmentation
Global Genetic Testing Market, By Type (Carrier Testing, Diagnostic Testing, New Born Screening, Predictive and Presymptomatic Testing, and Other Types), Technology (DNA sequencing, Polymerase Chain Reaction, Microarrays, Whole Genome Sequencing, Fluorescence In Situ Hybridization (FISH), and Others), Diseases (Rare Genetic Disorder, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntington’s Disease, Fragile X Syndrome, and Other Diseases), End User (Hospitals, Clinics, Diagnostic Centers, Private Clinics, Laboratory Service Providers, and Private Laboratories), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2031
Overview of Global Genetic Testing Market Dynamics
Driver
• Growing prevalence of genetic disorders
Restrain
• High cost of genetic testing
Opportunity
• Strategic initiatives by the key market player
Market Players
Some of the key market players for global genetic testing market are:
• Thermo Fisher Scientific Inc.
• Invitae Corporation
• Bio-Rad Laboratories, Inc.
• PerkinElmer Inc.
• Illumina, Inc.
• QIAGEN
• F. Hoffmann-La Roche Ltd.
• Fulgent Genetics
• Myriad Genetics, Inc.
• Abbott
• Eurofins Scientific
• Sorenson Genomics
• BIO-HELIX
• Biocartis
• Cepheid (A subsidiary of Danaher)
• PacBio
• ELITechGroup
• Genes2Me
• Eugene Labs
• Otogenetics
• Mapmygenome
• MedGenome
• BioReference
• Natera, Inc.
Table of Contents
1 INTRODUCTION 68
1.1 OBJECTIVES OF THE STUDY 68
1.2 MARKET DEFINITION 68
1.3 OVERVIEW OF THE GLOBAL GENETIC TESTING MARKET 68
1.4 LIMITATIONS 70
1.5 MARKETS COVERED 70
2 MARKET SEGMENTATION 73
2.1 MARKETS COVERED 73
2.2 GEOGRAPHICAL SCOPE 74
2.3 YEARS CONSIDERED FOR THE STUDY 75
2.4 CURRENCY AND PRICING 75
2.5 DBMR TRIPOD DATA VALIDATION MODEL 76
2.6 TYPE LIFELINE CURVE 80
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 81
2.8 DBMR MARKET POSITION GRID 82
2.9 MARKET APPLICATION COVERAGE GRID 83
2.10 VENDOR SHARE ANALYSIS 84
2.11 SECONDARY SOURCES 85
2.12 ASSUMPTIONS 85
3 EXECUTIVE SUMMARY 86
4 PREMIUM INSIGHTS 88
4.1 PESTAL ANALYSIS 91
4.2 PORTERS 5 FORCES 92
4.3 EPIDEMIOLOGY 93
5 GLOBAL GENETIC TESTING MARKET: REGULATIONS 94
6 MARKET OVERVIEW 96
6.1 DRIVERS 98
6.1.1 GROWING PREVALENCE OF GENETIC DISORDERS 98
6.1.2 INCREASE IN THE ADOPTION OF NEXT GENERATION SEQUENCING 98
6.1.3 WIDE PRODUCT PORTFOLIO OFFERED BY A MAJOR PLAYER 99
6.1.4 INCREASE THE TREND TOWARD PERSONALIZED MEDICATION 99
6.2 RESTRAINTS 100
6.2.1 HIGH COST OF GENETIC TESTING 100
6.2.2 CYBER SECURITY CONCERNS IN GENOMICS 101
6.3 OPPORTUNITIES 101
6.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER 101
6.3.2 TECHNOLOGICAL ADVANCEMENT IN THE FIELD OF GENETIC TESTING 102
6.3.3 INCREASING RESEARCH AND DEVELOPMENT FOR GENETIC TESTING 102
6.4 CHALLENGES 103
6.4.1 LACK OF SKILLED PROFESSIONALS TO PERFORM GENETIC TESTING 103
6.4.2 STRINGENT REGULATION POLICY FOR GENETIC TESTING 104
7 GLOBAL GENETIC TESTING MARKET, BY TYPE 105
7.1 OVERVIEW 106
7.2 DIAGNOSTIC TESTING 110
7.3 PRENATAL TESTING 110
7.3.1 NON-INVASIVE SCREENING 111
- 7.3.1.1 WHOLE GENOME SEQUENCING 112
- 7.3.1.2 COUNTING OF CFDNA FRAGMENTS 112
- 7.3.1.3 OTHERS 112
7.3.2 BY CONDITION 113
- 7.3.2.1 TRISOMY 21 113
- 7.3.2.2 KLINEFELTER SYNDROME 113
- 7.3.2.3 JACOBS SYNDROME 113
- 7.3.2.4 CYSTIC FIBROSIS 113
- 7.3.2.5 TURNER SYNDROME 114
- 7.3.2.6 TRISOMY 18 114
- 7.3.2.7 HEMOPHILIA 114
- 7.3.2.8 TRISOMY 13 114
- 7.3.2.9 MICRODELETION SYNDROME 114
- 7.3.2.10 FETAL GENDER 114
- 7.3.2.11 OTHERS 114
7.3.3 BY SCREENING TYPE 115
- 7.3.3.1 CARRIER SEQUENCING 115
- 7.3.3.2 SEQUENTIAL SEQUENCING 115
7.3.4 MATERNAL SERUM QUAD SCREENING 115
7.4 NEW-BORN SCREENING 116
7.4.1 SICKLE CELL DISEASE 116
7.4.2 CONGENITAL HYPOTHYROIDISM 117
7.4.3 PHENYLKETONURINA (PKU) 117
7.4.4 GALACTOSEMIA 117
7.4.5 MAPLE SYRUP URINE DISEASE 117
7.4.6 OTHERS 117
7.5 PREDICTIVE AND PRESYMPTOMATIC TESTING 117
7.6 CARRIER TESTING 118
7.6.1 MOLECULAR SCREENING TEST 118
7.6.2 BIOCHEMICAL SCREENING TEST 119
- 7.6.2.1 EXPANDED CARRIER SCREENING 119
- 7.6.2.2 PREDESIGNED PANEL TESTING 120
- 7.6.2.3 CUSTOM-MADE PANEL TESTING 120
- 7.6.2.4 TARGETED DISEASE CARRIER SCREENING 120
- 7.6.2.4.1 HEMATOLOGICAL CONDITIONS 120
- 7.6.2.4.2 PULMONARY CONDITIONS 121
- 7.6.2.4.3 NEUROLOGICAL CONDITIONS 121
- 7.6.2.4.4 OTHER CONDITIONS 121
7.7 OTHER TYPES 121
8 GLOBAL GENETIC TESTING MARKET, BY TECHNOLOGY 122
8.1 OVERVIEW 123
8.2 POLYMERASE CHAIN REACTION 126
8.2.1 REAL-TIME PCR (QPCR) 127
8.2.2 DIGITAL PCR (DPCR) 127
8.2.3 REVERSE TRANSCRIPTION PCR (RT-PCR) 127
8.2.4 HOT-START PCR 127
8.2.5 MULTIPLEX PCR 127
8.2.6 OTHER PCR 127
8.3 DNA SEQUENCING (NGS-BASED TESTING) 128
8.3.1 NEXT GENERATION SEQUENCING (NGS) 128
8.3.2 SANGER SEQUENCING (SINGLE GENE) 128
8.3.3 OTHER 129
8.4 WHOLE GENOME SEQUENCING 129
8.5 MICROARRAYS 129
8.5.1 DNA MICROARRAYS 130
8.5.2 PROTEIN MICROARRAYS 130
8.5.3 OTHER MICROARRAYS 130
8.6 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 130
8.7 OTHERS 131
9 GLOBAL GENETIC TESTING MARKET, BY DISEASES 132
9.1 OVERVIEW 133
9.2 CANCER 136
9.2.1 BREAST 137
9.2.2 COLON 137
9.2.3 LUNG 137
9.2.4 PROSTATE 137
9.2.5 OTHERS 137
9.3 SICKLE CELL ANEMIA 138
9.4 THALASSEMIA 138
9.5 RARE GENETIC DISORDER 139
9.5.1 TRISOMY 21 139
9.5.2 MONOSOMY X 139
9.5.3 TRISOMY 13 140
9.5.4 MICRODELETION SYNDROME 140
9.5.5 TRISOMY 18 140
9.5.6 OTHERS 140
9.6 FRAGILE X SYNDROME 140
9.7 DUCHENNE MUSCULAR DYSTROPHY 141
9.8 HUNTINGTON'S DISEASE 141
9.9 CYSTIC FIBROSIS 142
9.10 OTHERS 142
10 GLOBAL GENETIC TESTING MARKET, BY END USER 143
10.1 OVERVIEW 144
10.2 HOSPITALS 147
10.3 CLINICS 148
10.4 DIAGNOSTIC CENTERS 148
10.5 PRIVATE CLINICS 149
10.6 LABORATORY SERVICE PROVIDERS 149
10.7 PRIVATE LABORATORIES 150
11 GLOBAL GENETIC TESTING MARKET, BY REGION 151
11.1 OVERVIEW 152
11.2 NORTH AMERICA 155
11.2.1 U.S 165
11.2.2 CANADA 176
11.2.3 MEXICO 187
11.3 EUROPE 198
11.3.1 GERMANY 207
11.3.2 FRANCE 218
11.3.3 U.K 229
11.3.4 RUSSIA 240
11.3.5 ITALY 251
11.3.6 SPAIN 261
11.3.7 TURKEY 272
11.3.8 NETHERLANDS 283
11.3.9 SWITZERLAND 294
11.3.10 BELGIUM 305
11.3.11 REST OF EUROPE 316
11.4 ASIA-PACIFIC 317
11.4.1 CHINA 326
11.4.2 JAPAN 337
11.4.3 INDIA 348
11.4.4 SOUTH KOREA 359
11.4.5 AUSTRALIA 370
11.4.6 SINAGPORE 381
11.4.7 THAILAND 392
11.4.8 INDONESIA 403
11.4.9 PHILIPPINES 414
11.4.10 MALAYSIA 425
11.4.11 VIETNAM 436
11.4.12 REST OF ASIA-PACIFIC 447
11.5 SOUTH AMERICA 448
11.5.1 BRAZIL 456
11.5.2 ARGENTINA 466
11.5.3 REST OF SOUTH AMERICA 477
11.6 MIDDLE EAST AND AFRICA 478
11.6.1 SOUTH AFRICA 488
11.6.2 SAUDI ARABIA 499
11.6.3 U.A.E 510
11.6.4 ISRAEL 521
11.6.5 EGYPT 532
11.6.6 REST OF MIDDLE EAST AND AFRICA 543
12 GLOBAL GENETIC TESTING MARKET, COMPANY LANDSCAPE 544
12.1 COMPANY SHARE ANALYSIS: GLOBAL 544
13 NORTH AMERICA GENETIC TESTING MARKET, COMPANY LANDSCAPE 545
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 545
14 EUROPE GENETIC TESTING MARKET, COMPANY LANDSCAPE 546
14.1 COMPANY SHARE ANALYSIS: EUROPE 546
15 ASIA-PACIFIC GENETIC TESTING MARKET, COMPANY LANDSCAPE 547
15.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 547
16 SWOT ANALYSIS 548
17 COMPANY PROFILES 549
17.1 ILLUMINA, INC 549
17.1.1 COMPANY SNAPSHOT 549
17.1.2 REVENUE ANALYSIS 549
17.1.3 COMPANY SHARE ANALYSIS 550
17.1.4 PRODUCT PORTFOLIO 550
17.1.5 RECENT DEVELOPMENT 551
17.2 CEPHEID 552
17.2.1 COMPANY SNAPSHOT 552
17.2.2 REVENUE ANALYSIS 552
17.2.3 COMPANY SHARE ANALYSIS 553
17.2.4 PRODUCT PORTFOLIO 553
17.2.5 RECENT DEVELOPMENT 553
17.3 FULGENT GENETICS 554
17.3.1 COMPANY SNAPSHOT 554
17.3.2 REVENUE ANALYSIS 554
17.3.3 COMPANY SHARE ANALYSIS 555
17.3.4 PRODUCT PORTFOLIO 555
17.3.5 RECENT DEVELOPMENT 556
17.4 PERKINELMER INC 557
17.4.1 COMPANY SNAPSHOT 557
17.4.2 REVENUE ANALYSIS 557
17.4.3 COMPANY SHARE ANALYSIS 558
17.4.4 PRODUCT PORTFOLIO 558
17.4.5 RECENT DEVELOPMENT 558
17.5 THERMO FISHER SCIENTIFIC INC 559
17.5.1 COMPANY SNAPSHOT 559
17.5.2 REVENUE ANALYSIS 559
17.5.3 COMPANY SHARE ANALYSIS 560
17.5.4 PRODUCT PORTFOLIO 560
17.5.5 RECENT DEVELOPMENT 561
- 17.5.5.1 COLLABORATION 561
17.6 BIOREFERENCE 562
17.6.1 COMPANY SNAPSHOT 562
17.6.2 REVENUE ANALYSIS 562
17.6.3 PRODUCT PORTFOLIO 563
17.6.4 RECENT DEVELOPMENT 563
17.7 ELITECHGROUP 564
17.7.1 COMPANY SNAPSHOT 564
17.7.2 PRODUCT PORTFOLIO 564
17.7.3 RECENT DEVELOPMENTS 565
17.8 EUROFINS SCIENTIFIC 566
17.8.1 COMPANY SNAPSHOT 566
17.8.2 REVENUE ANALYSIS 566
17.8.3 PRODUCT PORTFOLIO 567
17.8.4 RECENT DEVELOPMENT 567
17.9 INVITAE CORPORATION 568
17.9.1 COMPANY SNAPSHOT 568
17.9.2 REVENUE ANALYSIS 568
17.9.3 PRODUCT PORTFOLIO 569
17.9.4 RECENT DEVELOPMENTS 569
17.10 MYRIAD GENETICS 570
17.10.1 COMPANY SNAPSHOT 570
17.10.2 REVENUE ANALYSIS 570
17.10.3 PRODUCT PORTFOLIO 571
17.10.4 RECENT DEVELOPMENT 571
17.11 ABBOTT 572
17.11.1 COMPANY SNAPSHOT 572
17.11.2 REVENUE ANALYSIS 572
17.11.3 PRODUCT PORTFOLIO 573
17.11.4 RECENT DEVELOPMENT 573
17.12 BIOCARTIS 574
17.12.1 COMPANY SNAPSHOT 574
17.12.2 REVENUE ANALYSIS 574
17.12.3 PRODUCT PORTFOLIO 575
17.12.4 RECENT DEVELOPMENTS 575
- 17.12.4.1 PARTNERSHIP 575
17.13 BIO-HELIX 576
17.13.1 COMPANY SNAPSHOT 576
17.13.2 PRODUCT PORTFOLIO 576
17.13.3 RECENT DEVELOPMENT 576
17.14 BIO-RAD LABORATORIES, INC 577
17.14.1 COMPANY SNAPSHOT 577
17.14.2 REVENUE ANALYSIS 577
17.14.3 PRODUCT PORTFOLIO 578
17.14.4 RECENT DEVELOPMENTS 578
17.15 EUGENE LABS 579
17.15.1 COMPANY SNAPSHOT 579
17.15.2 PRODUCT PORTFOLIO 579
17.15.3 RECENT DEVELOPMENT 579
17.16 F. HOFFMANN-LA ROCHE LTD 580
17.16.1 COMPANY SNAPSHOT 580
17.16.2 REVENUE ANALYSIS (PARENT COMPANY) 580
17.16.3 PRODUCT PORTFOLIO 581
17.16.4 RECENT DEVELOPMENT 581
17.17 GENES2ME 582
17.17.1 COMPANY SNAPSHOT 582
17.17.2 PRODUCT PORTFOLIO 582
17.17.3 RECENT DEVELOPMENT 582
17.18 MAPMYGENOME 583
17.18.1 COMPANY SNAPSHOT 583
17.18.2 PRODUCT PORTFOLIO 583
17.18.3 RECENT DEVELOPMENT 584
17.19 MEDGENOME 585
17.19.1 COMPANY SNAPSHOT 585
17.19.2 PRODUCT PORTFOLIO 585
17.19.3 RECENT DEVELOPMENT 586
17.20 NATERA, INC 587
17.20.1 COMPANY SNAPSHOT 587
17.20.2 REVENUE ANALYSIS 587
17.20.3 PRODUCT PORTFOLIO 588
17.20.4 RECENT DEVELOPMENT 589
17.21 OTOGENETICS 590
17.21.1 COMPANY SNAPSHOT 590
17.21.2 PRODUCT PORTFOLIO 591
17.21.3 RECENT DEVELOPMENT 591
17.22 PACBIO 592
17.22.1 COMPANY SNAPSHOT 592
17.22.2 REVENUE ANALYSIS 592
17.22.3 PRODUCT PORTFOLIO 593
17.22.4 RECENT DEVELOPMENT 593
17.23 QIAGEN 594
17.23.1 COMPANY SNAPSHOT 594
17.23.2 REVENUE ANALYSIS 594
17.23.3 PRODUCT PORTFOLIO 595
17.23.4 RECENT DEVELOPMENT 595
17.24 SORENSON GENOMICS 596
17.24.1 COMPANY SNAPSHOT 596
17.24.2 PRODUCT PORTFOLIO 596
17.24.3 RECENT DEVELOPMENT 596
18 QUESTIONNAIRE 597
19 RELATED REPORTS 600